Home
AKBA
AKBA News

Latest Akebia Therapeutics Inc. (AKBA) News on November 22, 2024

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

PR Newswire

8 days ago

Vadadustat Alternative Dosing Study Results Published in the American Journal of Kidney Disease

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

PR Newswire

10 days ago

Akebia Therapeutics to Present at the Jefferies London Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Simply Wall St.

13 days ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$5.50

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

GuruFocus.com

14 days ago

Akebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Zacks

15 days ago

Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

15 days ago

Akebia Therapeutics: Q3 Earnings Snapshot

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire

15 days ago

Akebia Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

20 days ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire

21 days ago

Akebia Therapeutics to Report Third Quarter 2024 Financial Results and Discuss Recent Business Highlights

High Growth Tech Stocks to Watch in October 2024

Simply Wall St.

a month ago

High Growth Tech Stocks to Watch in October 2024

MT Newswires

a month ago

Akebia Therapeutics Signs Contract to Expand Vafseo Access for Patients on Dialysis; Shares Rise

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire

a month ago

Akebia Therapeutics Signs Commercial Supply Contract with Leading Dialysis Organization to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

PR Newswire

a month ago

Akebia Therapeutics Announces Seven Poster Presentations at ASN Kidney Week 2024

MT Newswires

a month ago

Akebia Therapeutics Says Vafseo Granted TDAPA Reimbursement

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

PR Newswire

a month ago

CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

GuruFocus.com

a month ago

Akebia Therapeutics Inc (AKBA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

MT Newswires

a month ago

Akebia Therapeutics Enters Multi-Year Supply Contract With U.S. Renal Care for Vafseo

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire

a month ago

Akebia Therapeutics and U.S. Renal Care Sign Commercial Supply Contract to Enable Access to Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability

Simply Wall St.

2 months ago

Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Path To Profitability

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

2 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

PR Newswire

3 months ago

Akebia Therapeutics and U.S. Renal Care Initiate the VOICE Trial of Vafseo® (vadadustat) for Patients on Dialysis

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

3 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Zacks

3 months ago

Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?

Here's Why You Should Consider Buying Akebia (AKBA) Stock

Zacks

3 months ago

Here's Why You Should Consider Buying Akebia (AKBA) Stock

Akebia Therapeutics to Present at Upcoming Investor Conferences

PR Newswire

3 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

Zacks

3 months ago

Zacks Industry Outlook Highlights Corcept, Amneal, Bioventus, Foghorn and Akebia

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Zacks

3 months ago

5 Small Drug Stocks to Buy as Innovation Reaches Peak

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Zacks

3 months ago

Are Medical Stocks Lagging Acrivon Therapeutics, Inc. (ACRV) This Year?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets

Simply Wall St.

3 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Lifting Their Price Targets

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Zacks

3 months ago

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Associated Press Finance

3 months ago

Akebia Therapeutics: Q2 Earnings Snapshot

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire

3 months ago

Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire

4 months ago

Akebia Therapeutics to Report Second Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

4 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at Upcoming Investor Conferences

PR Newswire

4 months ago

Akebia Therapeutics to Present at Upcoming Investor Conferences

MT Newswires

4 months ago

Akebia Regains Full Rights to Sell Vafseo Tablets in US After Ending Licensing Deal With CSL Vifor

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

PR Newswire

4 months ago

Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

5 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

PR Newswire

5 months ago

Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference

MT Newswires

5 months ago

Akebia Therapeutics Names Erik Ostrowski CFO, CBO

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

PR Newswire

5 months ago

Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer

Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%

Simply Wall St.

5 months ago

Further weakness as Akebia Therapeutics (NASDAQ:AKBA) drops 16% this week, taking five-year losses to 80%

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

ACCESSWIRE

5 months ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Business Insider

5 months ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

GlobeNewswire

5 months ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Motley Fool

5 months ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

Unifor members vote to strike at Manitoba Hydro

CNW Group

5 months ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly

AFP

5 months ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Business Insider

5 months ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Here's what to do if you missed out on the massive 54% stock market rally since October 2022

Business Insider

5 months ago

Here's what to do if you missed out on the massive 54% stock market rally since October 2022

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

GlobeNewswire

5 months ago

[Latest] Global Virtual Reality In Gaming Market Size/Share Worth USD 103,244.7 Million by 2033 at a 16.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Business Wire

5 months ago

Net Asset Value(s)

CCF Group Successful €225m AT1 Issuance

Business Wire

5 months ago

CCF Group Successful €225m AT1 Issuance

Should You Hold 908 Devices (MASS)?

Insider Monkey

5 months ago

Should You Hold 908 Devices (MASS)?

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

GlobeNewswire

5 months ago

Bangladesh Ecommerce Market Report 2024, Featuring Daraz Bangladesh, Chaldal, Evaly, Pickaboo and Ajkerdeal - Forecasts to 2028

3 Major Product Releases at 3Shape Discover Event

PR Newswire

5 months ago

3 Major Product Releases at 3Shape Discover Event

Calculating The Fair Value Of Mincon Group plc (LON:MCON)

Simply Wall St.

5 months ago

Calculating The Fair Value Of Mincon Group plc (LON:MCON)

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

GlobeNewswire

5 months ago

Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

6 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

PR Newswire

6 months ago

Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

PR Newswire

6 months ago

Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference

Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Simply Wall St.

6 months ago

Revenue Downgrade: Here's What Analysts Forecast For Akebia Therapeutics, Inc. (NASDAQ:AKBA)

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

GuruFocus.com

6 months ago

Akebia Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Insider Monkey

6 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations

Simply Wall St.

6 months ago

Akebia Therapeutics First Quarter 2024 Earnings: Misses Expectations

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Zacks

6 months ago

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Associated Press Finance

6 months ago

Akebia Therapeutics: Q1 Earnings Snapshot

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

PR Newswire

6 months ago

Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

PR Newswire

7 months ago

Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

7 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

Simply Wall St.

7 months ago

When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

8 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Benzinga

8 months ago

FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

Zacks

8 months ago

Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

PR Newswire

8 months ago

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

Akebia Awaits FDA Word On Second Crack At Vadadustat

Barrons.com

8 months ago

Akebia Awaits FDA Word On Second Crack At Vadadustat

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

Simply Wall St.

8 months ago

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33

Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

Simply Wall St.

8 months ago

Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

GuruFocus.com

8 months ago

Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

Zacks

8 months ago

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

PR Newswire

8 months ago

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

PR Newswire

8 months ago

Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

9 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PR Newswire

10 months ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Secures $55 Million Term Loan Financing

PR Newswire

10 months ago

Akebia Secures $55 Million Term Loan Financing

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

ACCESSWIRE

10 months ago

Tortoise Announces 2023 Closed-End Fund Tax Characterization of Distributions and Release of Combined Annual Report

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024

PR Newswire

10 months ago

Bartesian Leverages Strategic Partnership with iHeartMedia to Drive Expansion in 2024

15 Highest Quality Multivitamin Brands of 2024

Insider Monkey

10 months ago

15 Highest Quality Multivitamin Brands of 2024

Denison Mine's (DNN) JV to Restart McClean Lake Mining Activity

Zacks

10 months ago

Denison Mine's (DNN) JV to Restart McClean Lake Mining Activity

JetBlue Warns It Might Scrap Spirit Airlines Takeover Next Week After Merger Block

The Wall Street Journal

10 months ago

JetBlue Warns It Might Scrap Spirit Airlines Takeover Next Week After Merger Block

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Insider Monkey

10 months ago

RBB Bancorp (NASDAQ:RBB) Q4 2023 Earnings Call Transcript

Best Value Stocks to Buy for January 25th

Zacks

10 months ago

Best Value Stocks to Buy for January 25th

Retail Dive

10 months ago

Solo Stove names 2 brand ambassadors

Zacks Industry Outlook Highlights American Water Works, California Water Service, SJW Group and Consolidated Water

Zacks

10 months ago

Zacks Industry Outlook Highlights American Water Works, California Water Service, SJW Group and Consolidated Water

Thomson Reuters StreetEvents

10 months ago

Q4 2023 Atlantic Union Bankshares Corp Earnings Call

Why RBB Bancorp Stock Bumped Higher Today

Motley Fool

10 months ago

Why RBB Bancorp Stock Bumped Higher Today

AllianceBernstein National Municipal Income Fund, Inc. Releases Monthly Portfolio Update

PR Newswire

10 months ago

AllianceBernstein National Municipal Income Fund, Inc. Releases Monthly Portfolio Update

ALLIANCEBERNSTEIN CLOSED-END FUNDS ANNOUNCE DISTRIBUTION RATES

PR Newswire

10 months ago

ALLIANCEBERNSTEIN CLOSED-END FUNDS ANNOUNCE DISTRIBUTION RATES

RBB Bancorp (RBB) Reports Increased Earnings and Strategic Initiatives in Q4 and Fiscal Year 2023

GuruFocus.com

10 months ago

RBB Bancorp (RBB) Reports Increased Earnings and Strategic Initiatives in Q4 and Fiscal Year 2023

Associated Press Finance

10 months ago

American National Bankshares: Q4 Earnings Snapshot

Share on Social Networks: